美国人类免疫缺陷病毒感染者的当前抗逆转录病毒治疗：综合临床系统艾滋病研究网络队列研究结果
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.
作者信息
Ma Jimmy, Nance Robin M, Delaney Joseph A C, Whitney Bridget M, Bamford Laura, Gravett Ronnie M, Moore Richard D, Napravnik Sonia, Mayer Kenneth H, Jacobson Jeffrey M, Christopoulos Katerina, Burkholder Greer A, Keruly Jeanne, Eron Joseph J, Martin Jeffrey, Cachay Edward R, Saag Michael S, Crane Heidi M, Kitahata Mari M
机构信息
Department of Medicine, University of Washington, Seattle, Washington, USA.
College of Pharmacy, University of Manitoba, Winnipeg, Manitoba, Canada.
出版信息
Clin Infect Dis. 2022 Sep 10;75(4):715-718. doi: 10.1093/cid/ciac086.
Abstract
Among 14 049 people with human immunodeficiency virus in care in 2019-2020, 96% were treated with antiretroviral therapy (ART). Current antiretroviral treatment patterns highlight high uptake of guideline-recommended ART regimens including second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) and tenofovir alafenamide, especially in antiretroviral-naive individuals initiating ART.
摘要
在2019年至2020年接受治疗的14049名艾滋病毒感染者中，96%接受了抗逆转录病毒疗法（ART）。目前的抗逆转录病毒治疗模式显示，指南推荐的抗逆转录病毒治疗方案，包括第二代整合酶链转移抑制剂（多替拉韦和比克替拉韦）和替诺福韦艾拉酚胺的使用率很高，尤其是在开始接受抗逆转录病毒治疗的初治个体中。
相似文献
1
Current Antiretroviral Treatment Among People With Human Immunodeficiency Virus in the United States: Findings from the Centers for AIDS Research Network of Integrated Clinic Systems Cohort.美国人类免疫缺陷病毒感染者的当前抗逆转录病毒治疗：综合临床系统艾滋病研究网络队列研究结果
Clin Infect Dis. 2022 Sep 10;75(4):715-718. doi: 10.1093/cid/ciac086.
2
Maintenance therapy with dolutegravir and lamivudine versus bictegravir, emtricitabine, and tenofovir alafenamide in people with HIV (PASO-DOBLE): 48-week results from a randomised, multicentre, open-label, non-inferiority trial.多替拉韦与拉米夫定维持治疗对比比克替拉韦、恩曲他滨和替诺福韦艾拉酚胺用于HIV感染者（PASO-DOBLE）：一项随机、多中心、开放标签、非劣效性试验的48周结果
Lancet HIV. 2025 Jul;12(7):e473-e484. doi: 10.1016/S2352-3018(25)00105-5. Epub 2025 Jun 7.
3
Successful viral suppression in a two-year-old child with human immunodeficiency virus infection treated with bictegravir/emtricitabine/tenofovir alafenamide.使用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺治疗的一名两岁人类免疫缺陷病毒感染儿童实现了病毒的成功抑制。
Turk J Pediatr. 2025 Jul 6;67(3):433-439. doi: 10.24953/turkjpediatr.2025.5998.
4
Dolutegravir plus boosted darunavir versus recommended standard-of-care antiretroviral regimens in people with HIV-1 for whom recommended first-line non-nucleoside reverse transcriptase inhibitor therapy has failed (DEFT): an open-label, randomised, phase 3b/4 trial.多替拉韦加利伟（商品名：特威凯）联合利托那韦增强的达芦那韦与推荐的标准护理抗逆转录病毒方案治疗推荐一线非核苷类逆转录酶抑制剂治疗失败的 HIV-1 感染者（DEFT）：一项开放标签、随机、3b/4 期试验。
Lancet HIV. 2024 Jul;11(7):e436-e448. doi: 10.1016/S2352-3018(24)00089-4. Epub 2024 May 21.
5
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption.在治疗中断后恢复使用或换用比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺的HIV感染者的治疗结果。
AIDS. 2025 Jul 15;39(9):1125-1132. doi: 10.1097/QAD.0000000000004171. Epub 2025 Mar 6.
6
Comparative safety of B/F/TAF versus other antiretroviral therapy regimens for treatment-naïve people with HIV-1: a systematic literature review and network meta-analysis.对于初治的HIV-1感染者，B/F/TAF与其他抗逆转录病毒治疗方案的比较安全性：一项系统文献综述和网状荟萃分析
J Comp Eff Res. 2025 Jul;14(7):e240231. doi: 10.57264/cer-2024-0231. Epub 2025 May 30.
7
Characterizing HIV drug resistance in cases of vertical transmission in the VESTED randomized antiretroviral treatment trial.在VESTED随机抗逆转录病毒治疗试验中对垂直传播病例的HIV耐药性进行特征分析。
J Acquir Immune Defic Syndr. 2024 Aug;96(4):385-392. doi: 10.1097/qai.0000000000003435.
8
Treatment persistence among treatment-experienced people with HIV switching to integrase strand transfer inhibitor-based antiretroviral regimens.转换为基于整合酶链转移抑制剂的抗逆转录病毒治疗方案的有HIV治疗经验者的治疗依从性。
J Med Econ. 2025 Jul 18:1-14. doi: 10.1080/13696998.2025.2536422.
9
Bictegravir/Emtricitabine/Tenofovir Alafenamide in Adults with HIV/HBV Coinfection: An Open-Label, Single-Arm, Safety and Efficacy Switch Study.比克替拉韦/恩曲他滨/丙酚替诺福韦用于成人HIV/ HBV合并感染：一项开放标签、单臂、安全性和有效性转换研究。
Viruses. 2025 Mar 31;17(4):510. doi: 10.3390/v17040510.
10
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.一线抗逆转录病毒疗法治疗 HIV 感染的疗效和安全性比较：系统评价和网络荟萃分析。
Lancet HIV. 2016 Nov;3(11):e510-e520. doi: 10.1016/S2352-3018(16)30091-1. Epub 2016 Sep 6.
本文引用的文献
1
Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options.在抗逆转录病毒治疗选择有限的情况下，大量接受过强化治疗的艾滋病毒感染者的病情大幅下降。
AIDS. 2020 Nov 15;34(14):2051-2059. doi: 10.1097/QAD.0000000000002679.
2
Changes in HIV antiretroviral prescribing practices in the United States.美国艾滋病毒抗逆转录病毒治疗处方实践的变化。
Int J STD AIDS. 2020 Jan;31(1):22-29. doi: 10.1177/0956462419880127. Epub 2019 Dec 2.
3
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.多替拉韦加拉米夫定与多替拉韦富马酸酯替诺福韦二吡呋酯和恩曲他滨在初治 HIV-1 感染的成人中的疗效比较（GEMINI-1 和 GEMINI-2）：两项多中心、双盲、随机、非劣效性、3 期临床试验的第 48 周结果。
Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9.
4
Antiretroviral treatment among commercially insured persons living with HIV in an era of universal treatment in the United States - 2012-2014.2012 - 2014年美国全民治疗时代商业保险覆盖的HIV感染者的抗逆转录病毒治疗情况
AIDS Care. 2018 Sep;30(9):1128-1134. doi: 10.1080/09540121.2018.1489099. Epub 2018 Jun 20.
5
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.替诺福韦艾拉酚胺与富马酸替诺福韦二吡呋酯、艾维雷韦、考比司他、恩曲他滨复方制剂，用于治疗人类免疫缺陷病毒 1 型感染的初始治疗：两项随机、双盲、III 期、非劣效性试验。
Lancet. 2015 Jun 27;385(9987):2606-15. doi: 10.1016/S0140-6736(15)60616-X. Epub 2015 Apr 15.
6
Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients.临床医生对延迟开始抗逆转录病毒治疗适用于临床的HIV感染患者的观点。
J Int Assoc Provid AIDS Care. 2015 May-Jun;14(3):245-54. doi: 10.1177/2325957414557267. Epub 2014 Nov 12.
7
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008.2000 年至 2008 年美国艾滋病毒感染者抗逆转录病毒治疗使用、HIV RNA 血浆病毒载量和 CD4 淋巴细胞计数的趋势。
Ann Intern Med. 2012 Sep 4;157(5):325-35. doi: 10.7326/0003-4819-157-5-201209040-00005.
8
Antiretroviral prescribing patterns in treatment-naïve patients in the United States.美国初治患者的抗逆转录病毒治疗方案。
AIDS Patient Care STDS. 2010 Feb;24(2):79-85. doi: 10.1089/apc.2009.0220.
9
Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems.队列简介：综合临床系统艾滋病研究网络中心
Int J Epidemiol. 2008 Oct;37(5):948-55. doi: 10.1093/ije/dym231. Epub 2008 Feb 8.
Zotero 插件